Search clinical trials for: TAK-648

Total 5347 results

Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Takeda

Completed

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

Healthy Volunteers

United States
Takeda

Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

Autoimmune Disease

United Kingdom
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Cancer

United States
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 2

Narcolepsy Type 2

Spain, United States, Japan, Italy, France, Germany, Australia, Netherlands, Finland, Norway, Sweden, Switzerland
Takeda

Completed

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Healthy Participants and Patients With Narcolepsy

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

Healthy Volunteers

United States
Takeda
Ovid Therapeutics Inc.

Completed

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Developmental and/or Epileptic Encephalopathies

United States
Takeda

Completed

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies

United States, Canada
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants

Ascending Single Dose Study
Takeda

Completed

Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Takeda

Terminated

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States
Takeda

Not yet recruiting

A Study of TAK-279 in Healthy Chinese Adults

Healthy Volunteers

China
Bradley A. McGregor, MD
Calithera Biosciences, Inc

Completed

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Takeda

Completed

A Study of Soticlestat Tablets in Healthy Adults

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)

Epilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)

United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
Takeda

Terminated

A Study of TAK-994 in Adults With Narcolepsy

Narcolepsy Type 1 (NT 1)

United States, Italy, Finland, Canada, Hungary, Czechia, France, Japan, Korea, Republic of, Spain
Takeda

Completed

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Neurocrine Biosciences
Takeda

Completed

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Healthy Volunteers

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Obstructive Sleep Apnea

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Advanced Malignant Solid Tumors

United States
Takeda

Completed

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Clinical Pharmacology

Japan
Takeda

Completed

Double-blind Comparative Study of TAK-875

Diabetes Mellitus

Japan
Takeda

Completed

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

Neuralgia, Postherpetic

Poland, United Kingdom, Germany, Bulgaria, Australia, Netherlands, Russian Federation, Czech Republic, South Africa
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Healthy Volunteers

United States
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, France, Hungary, Korea, Republic of, Belgium, Japan, Germany, Canada, Italy, Poland, Czechia, Denmark, Greece, Norway, Romania, Slovakia, United Kingdom
Takeda

Recruiting

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)

United States, China, Spain, France, Belgium, Australia, Brazil, Canada, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Serbia, Mexico, Russian Federation, Ukraine
Takeda
Michael J. Fox Foundation for Parkinson's Research

Completed

A Study of TAK-071 in People With Parkinson Disease

Parkinson Disease | Healthy Participants

United States
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 1

Narcolepsy Type 1

Spain, Japan, France, Germany, United States, Norway, Netherlands, Finland, Switzerland, Australia, Italy, Sweden
Takeda

Active, not recruiting

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

Spain, United States, Croatia, Italy, China, Germany, Bulgaria, Greece, Slovenia, Japan, Ukraine
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
Takeda

Terminated

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Narcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)

China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
Takeda

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

Healthy Volunteer

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

Healthy Participants | Narcolepsy

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants

Healthy Volunteers

Netherlands
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants

Dose Finding Study
Takeda

Completed

Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Takeda

Completed

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies

United States, Canada
Takeda
AstraZeneca

Recruiting

A Study of TAK-341 in Treatment of Multiple System Atrophy

Multiple System Atrophy

Spain, Germany, United States, Italy, United Kingdom, Austria, Denmark, France, Japan, Portugal
Takeda

Active, not recruiting

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Alagille Syndrome (ALGS)

Japan
Calithera Biosciences, Inc
Nektar Therapeutics

Withdrawn

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, Canada
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)

Complex Regional Pain Syndrome

United Kingdom

3

Subscribe